{
    "Case ID": "088407",
    "Crime_Name": [
        "Patent Infringement"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent validity and infringement"
    ],
    "Legal_Issue": [
        "Validity of AstraZeneca's omeprazole patents and whether Apotex infringes them"
    ],
    "Governing_Law": [
        "Patented Medicines (Notice of Compliance) Regulations",
        "Patent Act"
    ],
    "Procedural_Stage": [
        "Application under NOC Regulations"
    ],
    "Evidence_Assessment": [
        "Prior art demonstrating known antimicrobial effects and bioavailability enhancement of omeprazole",
        "Expert testimonies on inherent properties in prior treatments"
    ],
    "Decision_Outcome": [
        "AstraZeneca's application dismissed",
        "Patents invalidated for anticipation and obviousness"
    ],
    "Burden_of_Proof": [
        "On AstraZeneca to prove validity and infringement"
    ],
    "Credibility_Factor": [
        "Expert testimony credibility assessed in determining inherent properties"
    ],
    "Legal_Rule": [
        "Anticipation and obviousness as grounds for invalidating a patent"
    ],
    "Standard_of_Review": [
        "Balance of probabilities"
    ],
    "Procedural_Issue": [
        "Compliance with NOC Regulations procedural requirements"
    ],
    "Grounds_for_Claim": [
        "Alleged infringement of patents '668 and '762"
    ],
    "Outcome_on_Merits": [
        "Claim failed; patents found invalid"
    ],
    "Decision_Maker": [
        "Court"
    ],
    "Judicial_Review_Outcome": [
        "No judicial review requested; initial decision stands"
    ],
    "Review_Standard": [
        "Statutory interpretation and factual assessment under Patent Act"
    ],
    "Procedural_Fairness_Assessment": [
        "Fair hearing provided to both parties with opportunity to present evidence"
    ],
    "Key_Evidence_Considered": [
        "Prior art references",
        "Expert witness statements",
        "Patent claims analysis"
    ],
    "Legal_Framework": [
        "Statutory framework for patent protection and generic drug approval"
    ],
    "Applicant_Challenge": [
        "AstraZeneca sought to prevent Apotex from marketing generic omeprazole"
    ],
    "Court_Result": [
        "Dismissal of AstraZeneca's application"
    ],
    "Legal_Rule_Source": [
        "Patent Act",
        "NOCP Regulations"
    ],
    "Standard_of_Proof": [
        "Preponderance of evidence"
    ],
    "Defendant_Response": [
        "Denial of infringement and challenge to patent validity"
    ],
    "Evidence_Type": [
        "Documentary evidence",
        "Expert testimony",
        "Scientific literature"
    ],
    "Remedy_Requested": [
        "Interim injunction to prevent market entry by Apotex"
    ],
    "Outcome": [
        "Remedy denied; Apotex allowed to proceed"
    ],
    "Decision_Authority": [
        "Federal Court"
    ],
    "Remedy_Sought": [
        "Prevention of generic product launch pending patent expiry"
    ],
    "Resolution_Mechanism": [
        "Judicial determination under NOC proceedings"
    ],
    "Legal_Provision": [
        "Section 6 of the NOC Regulations",
        "Patent Act provisions on novelty and non-obviousness"
    ],
    "Authority": [
        "Canadian courts"
    ],
    "Claimant_Status": [
        "Patent holder (AstraZeneca)"
    ],
    "Legal_Provision_Cited": [
        "Patent Act, s. 28.3 (obviousness)",
        "s. 28.2 (anticipation)",
        "NOC Regulations, s. 6"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Invalidity due to anticipation and obviousness"
    ],
    "Applicable_Process": [
        "NOC proceeding for generic drug market authorization"
    ],
    "Outcome_of_Review": [
        "Patents invalidated; no infringement established"
    ],
    "Pending_Relief_or_Application": [
        "Application for prohibition of Apotex's product approval"
    ],
    "Jurisdiction": [
        "Canada"
    ],
    "Governing_Rule": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ]
}